Accelrys has completed its merger with Symyx Technologies. Under the terms of the transaction, Symyx stockholders will receive approximately 0.7802 shares of Accelrys common stock for each share of Symyx common stock they own. The merged entity will trade on the NASDAQ stock exchange as Accelrys, under the symbol ACCL.
'We are delighted that the merger of Accelrys and Symyx has now been completed, having received the full support of our collective stockholders, who recognise the inherent value offered by the combination,' said Max Carnecchia, chief executive officer of Accelrys. 'We welcome new SMMX stockholders, and also thank our customers, partners and employees for their ongoing support during the merger process. The new organisation creates a well-differentiated company that is uniquely qualified to be a leading force in the scientific informatics software industry.'
The combined entity enables customers to improve scientific performance by creating more open, flexible and agile environments, streamlining workflows, reducing operating costs, and increasing the potential for innovation. It has more than 1,350 customers, including 29 of the top 30 biopharmaceutical companies, all five top chemical companies, all five top aerospace companies, three of the five top consumer packaged goods companies, a number of top US Federal, and international government agencies, as well as many top academic institutions from around the world.
